CareDx Q3 2026: EPS tops estimates, full-year guidance raised
As seen on the 24/7 Wall St. homepage on October 29, 2026.
Adjusted EBITDA guidance now runs $90 million to $100 million, up from $66 million to $78 million, a step change in profitability investors were not underwriting. Testing Services volume rose 51% year over year, helped by the Naveris deal that closed July 1.
Continue ReadingShow less
CareDx posted adjusted earnings per share of $0.70 for the third quarter of 2026, far exceeding expectations, with revenue growing 39% year over year on strength in Testing Services.
Testing Services volume rose 51% year over year, with the July 1 close of the Naveris acquisition bringing NavDx revenue into the quarter for the first time.
Adjusted EBITDA margin expanded to roughly 22% from 15% a year ago, and management lifted full-year 2026 EBITDA and revenue guidance.
Sponsored
AlloHeme is targeting a first-quarter 2027 commercial launch, with HistoMap Kidney reaching broader availability in 2027 and both programs aiming for CLIA readiness before the end of 2026.
Operating cash flow declined to $12.7 million from $37.4 million a year ago, and the EPS figure benefited from an income tax benefit not adjusted out of the non-GAAP result.
Mentioned: CDNA